Featured Research

from universities, journals, and other organizations

Finishing the job of polio eradication worldwide is an ethical obligation: Experts

Date:
April 15, 2010
Source:
McLaughlin-Rotman Centre for Global Health
Summary:
Failure to pursue eradication of polio worldwide given the capacity and opportunity to do so is a violation of ethical principles, foremost among them a "duty to rescue" those in distress, say ethicists.

Failure to pursue eradication of polio worldwide given the capacity and opportunity to do so is a violation of ethical principles, foremost among them a "duty to rescue" those in distress, according to ethicists writing in this week's edition of the Lancet.

Claudia Emerson, PhD, Program Leader in Ethics, and Peter A. Singer, MD, Director of the Canadian-based McLaughlin-Rotman Centre for Global Health (MRC) at the University Health Network and University of Toronto, present a series of compelling arguments that completing polio eradication is an ethical imperative.

They say the polio eradication agenda in recent years has largely centered on questions of economic and technical feasibility and has come under fire from opponents who strongly support an 'effective control' strategy. However, it is estimated that this alternative to eradication would result in 4 million children contracting polio in the next 20 years.

The authors introduce a moral justification for eradication to the debate, asking: "How can we ethically justify this course of action when the opportunity and means to rescue are available?"

Examining only economic aspects of eradication overlooks "an important moral calculation: the human cost of failing to eradicate," they say. "This is the cost of lives not saved, the lives afflicted by polio (including those family members who care for paralysed children), and the impact of those lives on the future of the broader community."

"Obligations to future generations are difficult to define and may be limited, but if preventing harm is a moral duty, there may be a chain of obligation that persists through generations."

The eradication of smallpox, effectively accomplished in the late 1970s, has resulted in up to 2 million lives saved and 10-15 million smallpox infections prevented annually, the authors say.

"No one is further threatened by this disease. The eradication of polio would similarly achieve global public good. The Global Polio Eradication Initiative has already made strides in this direction: since its launch in 1988, over 2 billion children have been immunized and a 99% reduction in polio has been achieved. Arguably, those who enjoy the benefits of public goods ought to be motivated to act in pursuit of such goods, thus the onus is on the global community to continue supporting polio eradication efforts."

And self-interest adds a strong reason to pursue polio eradication, the authors say. Although polio has been absent from the developed world for over 30 years, the threat of re-emergence looms in a world where people and viruses easily cross international borders. Polio remains endemic in four countries -- India, Pakistan, Afghanistan, and Nigeria -- and over the years has been exported to previously polio-free countries in sub-Saharan Africa and elsewhere.

Conclude the authors: "We are on the last kilometre of a marathon; surely it is worth crossing the finish line."

The article will be published by the Lancet online April 15 and in the print edition April 17, a month prior to the start of the 63rd session of the World Health Assembly in May in Geneva, at which the Global Polio Eradication Initiative will present its aggressive new strategy aimed at wiping out polio in the next 3 years. The article also coincides with the 55th anniversary of the 1955 announcement by Jonas Salk of the world's first polio vaccine.


Story Source:

The above story is based on materials provided by McLaughlin-Rotman Centre for Global Health. Note: Materials may be edited for content and length.


Journal Reference:

  1. Claudia I. Emerson, Peter A. Singer. Is there an ethical obligation to complete polio eradication? The Lancet, 2010; 375 (9723): 1340-1341 DOI: 10.1016/S0140-6736(10)60565-X

Cite This Page:

McLaughlin-Rotman Centre for Global Health. "Finishing the job of polio eradication worldwide is an ethical obligation: Experts." ScienceDaily. ScienceDaily, 15 April 2010. <www.sciencedaily.com/releases/2010/04/100415185807.htm>.
McLaughlin-Rotman Centre for Global Health. (2010, April 15). Finishing the job of polio eradication worldwide is an ethical obligation: Experts. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2010/04/100415185807.htm
McLaughlin-Rotman Centre for Global Health. "Finishing the job of polio eradication worldwide is an ethical obligation: Experts." ScienceDaily. www.sciencedaily.com/releases/2010/04/100415185807.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins